JP5792630B2 - Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 - Google Patents

Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Download PDF

Info

Publication number
JP5792630B2
JP5792630B2 JP2011546814A JP2011546814A JP5792630B2 JP 5792630 B2 JP5792630 B2 JP 5792630B2 JP 2011546814 A JP2011546814 A JP 2011546814A JP 2011546814 A JP2011546814 A JP 2011546814A JP 5792630 B2 JP5792630 B2 JP 5792630B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
sequence
peptide
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011546814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516140A5 (https=
JP2012516140A (ja
Inventor
ダル ディガン フローレンス
ダル ディガン フローレンス
ジェイ．ニューマン マーク
ジェイ．ニューマン マーク
エル．アレキサンダー ジェフリー
エル．アレキサンダー ジェフリー
スコット　サウスウッド
サウスウッド スコット
Original Assignee
エピミューン，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピミューン，インコーポレイティド filed Critical エピミューン，インコーポレイティド
Publication of JP2012516140A publication Critical patent/JP2012516140A/ja
Publication of JP2012516140A5 publication Critical patent/JP2012516140A5/ja
Application granted granted Critical
Publication of JP5792630B2 publication Critical patent/JP5792630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011546814A 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Active JP5792630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14789209P 2009-01-28 2009-01-28
EP09151495 2009-01-28
EP09151495.0 2009-01-28
US61/147,892 2009-01-28
PCT/EP2010/050839 WO2010086294A2 (en) 2009-01-28 2010-01-26 Pan-dr binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2012516140A JP2012516140A (ja) 2012-07-19
JP2012516140A5 JP2012516140A5 (https=) 2013-03-14
JP5792630B2 true JP5792630B2 (ja) 2015-10-14

Family

ID=42025833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546814A Active JP5792630B2 (ja) 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用

Country Status (4)

Country Link
US (2) US9249187B2 (https=)
EP (1) EP2391635B1 (https=)
JP (1) JP5792630B2 (https=)
WO (1) WO2010086294A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
AU2014296038B2 (en) 2013-07-31 2020-09-10 Bioventures, Llc. Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
AU2016306304A1 (en) 2015-08-07 2018-03-22 The University Of Birmingham Identification of class I MHC associated glycopertides as targets for cancer immunotherapy
CN109748952B (zh) 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
CN112469661B (zh) * 2018-06-13 2024-04-26 斯克里普斯研究学院 具有新结构组分的纳米粒疫苗
US20220383996A1 (en) 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants
WO2025231560A1 (en) * 2024-05-08 2025-11-13 The Governing Council Of The University Of Toronto Vaccine to mobilize b cells for therapy

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
HUT68510A (en) 1991-08-26 1995-06-28 Cytel Corp Process for producing hla-restricted hapatitis b virus ctl epitopes and pharmaceutical compositions containing them
ZA926440B (en) 1991-08-26 1993-06-07 Scripps Research Inst Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus.
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
US20040096445A1 (en) 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
AU695261B2 (en) 1993-02-26 1998-08-13 Scripps Research Institute, The Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
CN1118572A (zh) 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
AU6916694A (en) 1993-05-19 1994-12-12 Cytel Corporation Novel treatments for allergic diseases
DK0726758T3 (da) 1993-08-02 2003-03-03 Scripps Research Inst Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
DE69430315T2 (de) 1993-08-06 2002-11-21 Epimmune, Inc. Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl
JPH09502086A (ja) 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
AU698962B2 (en) * 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
WO1996040213A1 (en) 1995-06-07 1996-12-19 Cytel Corporation Manufacture and purification of peptides
DE69714011T2 (de) 1996-01-24 2003-02-27 Epimmune, Inc. Die erzeugung einer immunantwort gegen erwünschte determinanten
JP2001504799A (ja) * 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Ｈｌａ分子への結合アフィニティーが増加したペプチド
DE69733352T2 (de) 1996-03-21 2006-04-27 Epimmune, Inc., San Diego Hla-a2.1 bindende peptide und deren verwendung
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
WO2004089973A2 (en) 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
WO1998033888A1 (en) 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
PT1447414E (pt) 1997-10-10 2007-07-18 Us Gov Health & Human Serv Péptidos antagonistas do antigénio carcinoembrionário ( cea ).
EP1064022A4 (en) 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
CA2685270C (en) 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
AU4224499A (en) * 1998-05-29 1999-12-13 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
CA2330824A1 (en) 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
IL141868A0 (en) 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
WO2000044775A2 (en) 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
EP1200109A4 (en) 1999-07-19 2005-06-15 Epimmune Inc USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
JP4873810B2 (ja) 1999-10-05 2012-02-08 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導
AU1661201A (en) 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CA2393339A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
AU2088701A (en) 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
US20040146519A1 (en) 1999-12-10 2004-07-29 John Fikes Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
AU2087401A (en) 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
EP1242049A4 (en) 1999-12-13 2005-01-05 Epimmune Inc VACCINE COMPOSITIONS AND ANTIGEN PEPTIDES ASSOCIATED WITH CLASS I HLA-A2 TUMOR
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
CA2394741A1 (en) 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
MXPA02006554A (es) 1999-12-28 2003-09-22 Epimmune Inc Minigenes optimizados y peptidos codificados por los mismos.
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CN1452634A (zh) 2000-02-23 2003-10-29 埃皮缪纳股份有限公司 Hla结合肽及其用途
WO2002020616A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla-a2.1 binding peptides and their uses
AU2000273396A1 (en) 2000-09-01 2002-03-22 Epimmune, Inc. Hla binding peptides and their uses
EP1313505A4 (en) 2000-09-01 2005-10-12 Epimmune Inc HLA BINDING PEPTIDES AND THEIR USES (18.03.02)
JP2004508320A (ja) 2000-09-08 2004-03-18 エピミューン　インコーポレイテッド ペプチドおよび核酸組成物を用いるｂ型肝炎ウイルスに対する細胞性免疫応答の誘導
EP1911461B1 (en) 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
EP1495322A4 (en) 2002-04-05 2006-09-06 Epimmune Inc HETEROKLITIC ANALOGUES AND ASSOCIATED METHODS
WO2004031210A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
US8017745B2 (en) 2002-12-06 2011-09-13 Epimmune Inc. Plasmodium falciparum antigens and methods of use
CA2511775A1 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
US20070054262A1 (en) 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
ES2456666T3 (es) 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
AU2005250170A1 (en) 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
WO2005120563A2 (en) 2004-06-04 2005-12-22 Pharmexa Inc. Induction of an immune response against streptococcus pneumoniae polysaccharides
US9511134B2 (en) * 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2007137586A2 (en) * 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides
WO2008039267A2 (en) 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US9910646B2 (en) 2015-12-26 2018-03-06 Intel Corporation Technologies for native code invocation using binary analysis

Also Published As

Publication number Publication date
US20160114035A1 (en) 2016-04-28
EP2391635A2 (en) 2011-12-07
US9249187B2 (en) 2016-02-02
WO2010086294A3 (en) 2010-11-25
EP2391635B1 (en) 2017-04-26
US20110293646A1 (en) 2011-12-01
WO2010086294A2 (en) 2010-08-05
US9789181B2 (en) 2017-10-17
JP2012516140A (ja) 2012-07-19

Similar Documents

Publication Publication Date Title
JP5792630B2 (ja) Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
US6413935B1 (en) Induction of immune response against desired determinants
Moyle et al. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
EP2247306B1 (en) Immunogenic control of tumours and tumour cells
JP4063879B2 (ja) 所望の決定基に対する免疫応答の誘導
EP0907370B1 (en) Hla-a2.1 binding peptides and their uses
US20220273790A1 (en) Rationally engineered carrier proteins for vaccines
JPH03173830A (ja) ワクチン組成物
CA2386341A1 (en) Heteroclitic analogs and related methods
Abdel-Aal et al. Structure–activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates
JP2010535026A (ja) 多量体マルチエピトープインフルエンザワクチン
CN113015541A (zh) 具有新氧化还原酶基序的免疫原性肽
McDonald et al. Synthesis of a self-adjuvanting MUC1 vaccine via diselenide-selenoester ligation-deselenization
US20050049197A1 (en) Induction of immune response against desired determinants
US20260001938A1 (en) Peptide used for immunotherapeutics
EP4138901A1 (en) Compositions and methods for inducing immune responses against class i fusion protein viruses
Gras-Masse Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations
WO2010027973A1 (en) Human papillomavirus / li-key hybrids and methods of use
US20150203830A1 (en) Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes
US20250332246A1 (en) Enhanced expression via autotransporters
CN100368436C (zh) 人绒毛膜促性腺激素重组多表位嵌合肽cp22抗原的分子设计及其制备方法
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
CN117957017A (zh) 包含重组重叠肽和天然蛋白质的疫苗制剂
CN116528882A (zh) 用于免疫治疗剂的肽
CN1913918A (zh) 用作免疫佐剂的gm1结合缺陷的外毒素

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150806

R150 Certificate of patent or registration of utility model

Ref document number: 5792630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250